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OBJECTIVE: The purpose of this investigation was to
compare the experiences of two US corporations, each
employing over 50,000 workers and each offering a com-
prehensive benefit package, in terms of direct (i.e., medi-
cal and pharmaceutical) and indirect (i.e., sick leave and
disability) costs of illness. METHODS: Based on a 1996
sample of workers (n  9439), retrospective medical and
pharmaceutical claims at the employee level were linked
with contemporaneous archival measures of productiv-
ity, including sick leave and disability. These results were
normalized to the age-gender distribution of the US labor
force. To assess the comparability of experiences at each
company, direct and indirect burdens of illness were ex-
amined both in the aggregate as well as at the disease-
group level. RESULTS: The average annual cost of illness
per employee was $3,272 in Company A (59% medical,
9% pharmaceutical, and 32% work loss) and $3,574 in
Company B (44% medical, 9% pharmaceutical, and
47% work loss). Although musculoskeletal diseases rep-
resented the greatest total cost outlay for both companies
(i.e., 10% at Company A, 16% at Company B), the dis-
tribution of direct and indirect costs varied by diagnostic
grouping. CONCLUSIONS: A traditional focus on direct
costs alone would vastly understate the impact of illness
to the employer, since for every dollar of direct expendi-
tures, these companies spent between $0.47 and $0.87 on
additional indirect costs. Worksite and employee health
management programs tailored to the characteristics of
the particular workforce in question could help maximize
return on investment in employee health.
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Health Outcomes Research (OR) groups exist in most
major pharmaceutical companies and are currently chal-
lenged to quantify their productivity and value to the or-
ganization. Per a recent Tufts survey, industry leaders ex-
pect continued growth in OR departments substantiating
the need for metrics. METHODS: Our OR Department,
positioned within Clinical Research, was approached by
upper management to create a metrics reporting system.
The group discussed a comprehensive list of departmen-
tal activities until core items were agreed upon. Using a
0-10 scale, items were ranked by perceived value to the
company using the Delphi technique. To approximate
time expenditure, complexity categories (1  simple, 2 
moderate, 3  complex), based on estimates of average
number of workdays to complete each activity, were as-
signed to each item. RESULTS: An initial list of 20 items
was reduced by the group to yield 11 core items: publica-
tions (1.8  Delphi weight), models (1.4), strategic plans
(1.3), protocols (0.9), instrument development (0.9), re-
search reports (0.9), abstracts (0.7), reviews (0.6), analy-
sis plans (0.6), presentations (0.5), IPMs (0.4). The value-
score was generated by multiplying the count of each
item by its Delphi-weight then summed to result in a
composite value-score. The complexity-score was calcu-
lated similarly. These two scores, reported separately to
enhance understanding of both output and labor, were
divided by the number of team members to produce pro-
ductivity units per headcount. CONCLUSION: This met-
rics system represents one approach to valuing OR group
contributions. We have implemented a validation and
QA process to observe performance over time and assess
appropriateness of the items selected. This system does
not capture activities conducted to support departmental
and organizational infrastructure. Therefore, is not ap-
propriate for calculating standard costs or for valuing all
contributions attributable to OR groups. In addition to
concisely communicating OR activities to upper-manage-
ment, metrics help team members focus on value-added
activities and project prioritization.
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OBJECTIVES: Consumer preferences and willingness-to-
pay (WTP) were measured for a new dental anesthetic
(dental gel) versus existing anesthetic options for peri-
odontal recall cleanings. METHODS: The study was
conducted by developing and administering a computer-
based interactive survey to study subjects. First, clinical
information was provided, describing periodontal dis-
ease, recall cleaning visits, and anesthetic options (no
freezing, dental needle, and dental gel). Subjects were
asked to choose which freezing option they would prefer,
if they required freezing. Strength of preference for dental
gel was measured using WTP: (1) at the subject’s point of
consumption, and (2) as a monthly dental insurance pre-
mium, for any dental plan beneficiary at the point of con-
sumption. RESULTS: Both recall patients (n  97) and
general population subjects (n  196) participated in the
study. The majority of general subjects (81.0%) and re-
call subjects (82.5%) chose dental gel over other options.
The majority of general subjects (86.7%) and recall sub-
jects (83.8%) who preferred dental gel were willing to
pay for dental gel. The median WTP to have dental gel
available at the point of consumption was $20.00 per
visit for the general population, and $10.00 for the recall
population. The majority of general subjects (72.4%)
and recall subjects (73.2%) were willing to pay an insur-
ance premium for dental gel, even if they did not person-
ally prefer dental gel. The median monthly premium was
$2.00 per month for both groups. CONCLUSIONS:
Dental gel was overwhelmingly preferred by general and
